Background
Methods
Plant material
Extract preparation
Ethics statement
Experimental animals
Myocardial infarction model
Echocardiographic measure of cardiac function
Hemodynamic measurement
Myocardial enzymes and inflammatory cytokines measurement in serum
Infarct size evaluation
Western blot analysis
Statistical analysis
Results
GXD improved cardiac function caused by cardiac fibrosis
sham | MI | GXDL | GXDH | |
---|---|---|---|---|
HR(beats/min) | 359.6 ± 42.3 | 259.8 ± 29.5△△
| 306.0 ± 55.4*
| 333.7 ± 57.2**
|
SBP(mmHg) | 107.1 ± 10.1 | 82.9 ± 7.7△△
| 88.4 ± 7.3 | 99.1 ± 10.2**
|
DBP(mmHg) | 69.93 ± 10.47 | 56.48 ± 8.07△△
| 62.59 ± 5.26*
| 67.26 ± 11.65*
|
+LV dp/dtmax(mmHg/s) | 5287.03 ± 1247.53 | 3312.07 ± 859.48△△
| 4062.42 ± 623.19*
| 4752.61 ± 930.10**
|
-LV dp/dtmin(mmHg/s) | 4099.12 ± 759.61 | 3005.07 ± 517.25△△
| 3357.75 ± 774.67 | 3822.46 ± 905.39*
|
LVSP(mmHg) | 120.99 ± 10.15 | 88.94 ± 6.86△△
| 95.70 ± 7.57*
| 105.24 ± 9.85**
|
LVEDP(mmHg) | −4.57 ± 1.71 | 5.72 ± 1.44△△
| 2.69 ± 0.88**
| −0.98 ± 1.70**
|